USPTO serial 90364536
BIOLOGY TO BARCODES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 7, 2025
- Examiner
- GOODWIN, KATRINA JOYE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BIOLOGY TO BARCODES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh AUGUSTINE
Leigh AUGUSTINE EIP US LLP4600 S. Syracuse Street, 9th FloorDenver, CO 80237United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Chemical reagents for medical or veterinary purposes; Clinical medical reagents; Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical and veterinary use; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic preparations for veterinary purposes; Diagnostic reagents for medicinal use; Enzyme preparations for medical purposes; Enzyme preparations for veterinary purposes; Enzymes for medical purposes; Enzymes for veterinary purposes; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing body fluids for microorganisms; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Medical diagnostic test strips for use in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Medical diagnostic test strips for blood analysis, urine analysis, saliva analysis, water analysis, and liquid biopsy; Nucleic acid sequences and chemical reagents for medical and veterinary purposes | ACTIVE | Mar 30, 2021 |
| 010 | Blood collection kit comprised of blood collection bag, holder for medical sample tubes and vials, and medical sample tubes and vials; Blood component separation apparatus for medical purposes; Blood containers for medical purposes; Blood filters; Blood testing apparatus, namely, blood collecting tubes; Blood testing apparatus, namely, blood sampling tubes; Filters for blood and blood components for medical purposes; Medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; Medical apparatus for detecting cancer; Medical apparatus for diagnosing or treating respiratory conditions; Medical apparatus for diagnosing or treating respiratory conditions, namely, cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Medical device and surgical instrument for use in diagnosis and surgery of the gastro-intestinal tract; Medical device for detecting cancer; Medical devices for dosimetry purposes in the field of radiotherapy; Medical devices for use in treating or diagnosing cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Medical devices for use in treating or diagnosing cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk with integrated recorded operating system software, sold as a unit; Medical devices for use in treating or diagnosing cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk with integrated recorded software for detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways, sold as a unit; Medical diagnostic apparatus for detecting cancer; Medical diagnostic apparatus for testing DNA and RNA samples; Medical diagnostic apparatus for testing for viruses; Medical diagnostic apparatus for testing the presence of nucleic acids and antigens, and modifications thereof, gene expression, tissue structures, radiation exposure; Medical diagnostic apparatus for testing biological samples, DNA, RNA, proteins, viruses, single cells, tissue, organs, biochemical preparations, and waste water incorporating recorded operating system software; Medical diagnostic instruments for the analysis of body fluids; Medical instruments for analysing and identifying bacteria; Medical instruments for analyzing and identifying bacteria; Medical instruments for use in treating cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Medical instruments, namely, biosensors for detecting infectious diseases; Medical specimen collection devices in the nature of bottles, tubes, swabs, syringes, and wipes for the collection of nasal mucus, respiratory droplets, saliva, blood, urine, and feces; Sample preparation device for medical diagnostic uses | ACTIVE | Mar 30, 2021 |
| 044 | DNA screening for medical purposes; Genetic testing for medical purposes; Genetic testing of animals for diagnostic or treatment purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services for the diagnosis of cancer; Medical diagnosis and treatment of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Medical diagnosis of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Medical diagnostic testing, monitoring and reporting services; Medical dosimetry services for treating radiation exposure; Medical screening; Medical screening services in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Medical services; Medical testing for diagnostic or treatment purposes; Medical testing of urine, blood, hair follicles and breath; Providing cancer screening services; Providing information in the field of cancer prevention, screening, diagnosis and treatment; Providing information in the field of diabetes; Veterinary specialty services providing advanced medical, diagnostic or surgical services for animals | ACTIVE | Mar 30, 2021 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BioSpyder Technologies, Inc.
- Other trademarks owned by BioSpyder Technologies, Inc.
- Other trademarks owned by BioSpyder Technologies, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 044
- Similar marks named BIOLOGY TO BARCODES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 7, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 7, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 18, 2024 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Dec 18, 2024 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Dec 10, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 10, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 10, 2024 | ALIE | ASSIGNED TO LIE | — |
| Oct 31, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 31, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 1, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 1, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 1, 2024 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 15, 2024 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Feb 14, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 24, 2024 | IUAF | USE AMENDMENT FILED | — |
| Jan 24, 2024 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Aug 5, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 3, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 3, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 3, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 10, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 10, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 10, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 2, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 31, 2023 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 31, 2023 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 31, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 2, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 29, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 29, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 29, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 5, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 3, 2022 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 3, 2022 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 3, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 13, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 13, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 13, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 3, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 8, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 8, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 19, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 3, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 26, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 12, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 10, 2020 | NWAP | NEW APPLICATION ENTERED | — |